Ask AI
See Activity Collection
ProCE Banner Activity

Transforming Lymphoma Management: Practical Integration of CAR T-Cell Therapies for Improved Outcomes

Slideset

CAR T-cell therapy is an established treatment option for patients with R/R B-cell lymphomas, but successful use requires timely referral, coordinated care, and proactive management of treatment-related toxicities. This slideset reviews current evidence and practical considerations for CAR T-cell therapy, including patient referral and preparation, treatment logistics, and strategies for recognizing and managing acute and late adverse events.

Released: September 09, 2026

Begin Activity

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Krish Patel

Krish Patel, MD

Executive Director, Hematologic Cancer Research
Director, Lymphoma Research Program
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee
Jason Westin

Jason Westin, MD, MS, FACP, FASCO

Professor, Department of Lymphoma & Myeloma
Lead, Lymphoma & Myeloma Service Line
Director, Lymphoma Clinical Research
MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, physician assistants, nurse practitioners, clinical nurse specialists, nurses, pharmacists, and other healthcare professionals who care for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to select appropriate candidates for CAR T-cell therapy in DLBCL, FL, MCL, MZL, and CLL/SLL, applying current evidence and FDA-approved indications

  • Construct comprehensive care plans for patients undergoing CAR T-cell therapy, including referral, pretreatment preparations, and posttreatment monitoring

  • Formulate evidence-based management strategies for CAR T-cell therapy-related adverse events, including cytokine release syndrome and neurotoxicity

  • Evaluate ongoing clinical trials and emerging data on CAR T-cell therapies for B-cell malignancies to guide appropriate patient enrollment and integrate new findings into clinical practice

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.